Human Papillomavirus Infections - Pipeline Review, H2 2012

Global Markets Direct, September 2012, Pages: 123

Human Papillomavirus Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Human Papillomavirus Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Human Papillomavirus Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Human Papillomavirus Infections. Human Papillomavirus Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Human Papillomavirus Infections.
- A review of the Human Papillomavirus Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Human Papillomavirus Infections pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Human Papillomavirus Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Human Papillomavirus Infections pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Human Papillomavirus Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Human Papillomavirus Infections 11
Human Papillomavirus Infections Therapeutics under Development by Companies 13
Human Papillomavirus Infections Therapeutics under Investigation by Universities/Institutes 17
Late Stage Products 18
Comparative Analysis 18
Mid Clinical Stage Products 19
Comparative Analysis 19
Early Clinical Stage Products 20
Comparative Analysis 20
Discovery and Pre-Clinical Stage Products 21
Comparative Analysis 21
Human Papillomavirus Infections Therapeutics – Products under Development by Companies 22
Human Papillomavirus Infections Therapeutics – Products under Investigation by Universities/Institutes 23
Companies Involved in Human Papillomavirus Infections Therapeutics Development 24
Helix BioPharma Corp. 24
Valeant Pharmaceuticals International 25
Inovio Biomedical Corporation 26
Merck & Co., Inc. 27
MediGene AG 28
Chong Kun Dang Pharmaceutical 29
Alfacell Corporation 30
Crucell N.V. 31
Bio-Bridge Science, Inc. 32
Starpharma Holdings Limited 33
Anaconda Pharma 34
Nutri Pharma ASA 35
BioMAS Ltd. 36
Telormedix SA 37
ApoImmune, Inc. 38
PDS Biotechnology Corporation 39
Lumavita AG 40
ImmunoVaccine Technologies Inc. 41
BT PHARMA 42
Cutanea Life Sciences 43
Genetic Immunity, LLC 44
IRX Therapeutics, Inc. 45
Moberg Derma AB 46
Selecta Biosciences, Inc. 47
Inviragen, Inc. 48
EyeGene, Inc. 49
FunZyme BioTechnologies S.A. 50
Coridon Pty Ltd 51
Human Papillomavirus Infections – Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 58
PDS-0101 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
interferon alpha-2b - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Veregen - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
TMX-202 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
ApoVax-104-HPV - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
LMV-601 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
IRX-3 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ProCervix - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
V-503 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
AS-101 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Candin - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Human Papillomavirus Quadrivalent Vaccine - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
SPL-7013 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
cidofovir - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
plerixafor - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SGN-00101 Vaccine - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Albuterpenoid - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Albuterpenoid - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
HPV Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 82
HPV Vaccine - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
HupaDerm Vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
Human Papillomavirus Vaccine - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
RBT-201 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
imiquimod - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
silgard - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
HPV Vaccine - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
rAmphinase 2 - Drug Profile 90
Product Description 90
Mechanism of Action 90
R&D Progress 90
Adeno-Associated Virus-Like Particles - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
EG-HPV - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
AP-611074 - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
IDP-109 - Drug Profile 96
Product Description 96
Mechanism of Action 96
R&D Progress 96
SynCon HPV Vaccine - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
Human Papillomavirus Vaccine - Drug Profile 98
Product Description 98
Mechanism of Action 98
R&D Progress 98
HPV Vaccine - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
CKD-12201 - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Universal HPV Vaccine - Drug Profile 102
Product Description 102
Mechanism of Action 102
R&D Progress 102
PL-202 - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
Human Papillomavirus Infections Therapeutics – Drug Profile Updates 104
Human Papillomavirus Infections Therapeutics – Discontinued Products 112
Human Papillomavirus Infections Therapeutics - Dormant Products 113
Human Papillomavirus Infections – Product Development Milestones 116
Featured News & Press Releases 116
Jul 12, 2012: HPV Vaccine Extended To Boys In Australia 116
Jun 07, 2012: Bionor Pharma Submits International Patent Application For Human Papillomavirus Vaccine 116
Apr 10, 2012: Medigene Presents Preclinical AAVLP Data At World Vaccine Congress 117
Mar 15, 2012: Photocure Presents Clinical Data Of Cevira At American Society Of Colposcopy And Cervical Pathology 117
Mar 05, 2012: Inovio Therapeutic Vaccine For Head & Neck And Other HPV-Related Cancers Induces Robust T-Cell Immune Response In Mice 118
Feb 20, 2012: Genticel Completes Recruitment For Phase Ib Vaccine Trial In Women Infected With High-Risk HPV 119
Jan 26, 2012: Hemispherx Biopharma Gains Regulatory Approval In Latin America For Alferon N Injection 119
Jan 25, 2012: Kaiser Permanente Study Finds Gardasil Does Not Trigger Lupus, Rheumatoid Arthritis Or Type 1 Diabetes After Vaccination 120
Jan 19, 2012: National Advisory Committee On Immunization Recommends Merck's GARDASIL 121
Jan 03, 2012: Photocure Completes Enrollment In Phase IIb Study Of Cevira 121
Appendix 122
Methodology 122
Coverage 122
Secondary Research 122
Primary Research 122
Expert Panel Validation 122
Contact Us 123
Disclaimer 123

List of Tables
Number of Products Under Development for Human Papillomavirus Infections, H2 2012 11
Products under Development for Human Papillomavirus Infections – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Number of Products under Development by Companies, H2 2012 (Contd..2) 16
Number of Products under Investigation by Universities/Institutes, H2 2012 17
Comparative Analysis by Late Stage Development, H2 2012 18
Comparative Analysis by Mid Clinical Stage Development, H2 2012 19
Comparative Analysis by Early Clinical Stage Development, H2 2012 20
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 21
Products under Development by Companies, H2 2012 22
Products under Investigation by Universities/Institutes, H2 2012 23
Helix BioPharma Corp., H2 2012 24
Valeant Pharmaceuticals International, H2 2012 25
Inovio Biomedical Corporation, H2 2012 26
Merck & Co., Inc., H2 2012 27
MediGene AG, H2 2012 28
Chong Kun Dang Pharmaceutical, H2 2012 29
Alfacell Corporation, H2 2012 30
Crucell N.V., H2 2012 31
Bio-Bridge Science, Inc., H2 2012 32
Starpharma Holdings Limited, H2 2012 33
Anaconda Pharma, H2 2012 34
Nutri Pharma ASA, H2 2012 35
BioMAS Ltd., H2 2012 36
Telormedix SA, H2 2012 37
ApoImmune, Inc., H2 2012 38
PDS Biotechnology Corporation, H2 2012 39
Lumavita AG, H2 2012 40
ImmunoVaccine Technologies Inc., H2 2012 41
BT PHARMA, H2 2012 42
Cutanea Life Sciences, H2 2012 43
Genetic Immunity, LLC, H2 2012 44
IRX Therapeutics, Inc., H2 2012 45
Moberg Derma AB, H2 2012 46
Selecta Biosciences, Inc., H2 2012 47
Inviragen, Inc., H2 2012 48
EyeGene, Inc., H2 2012 49
FunZyme BioTechnologies S.A., H2 2012 50
Coridon Pty Ltd, H2 2012 51
Assessment by Monotherapy Products, H2 2012 52
Assessment by Stage and Route of Administration, H2 2012 54
Assessment by Stage and Molecule Type, H2 2012 57
Human Papillomavirus Infections Therapeutics – Drug Profile Updates 104
Human Papillomavirus Infections Therapeutics – Discontinued Products 112
Human Papillomavirus Infections Therapeutics – Dormant Products 113
Human Papillomavirus Infections Therapeutics – Dormant Products (Contd..1) 114
Human Papillomavirus Infections Therapeutics – Dormant Products (Contd..2) 115

List of Figures
Number of Products under Development for Human Papillomavirus Infections, H2 2012 11
Products under Development for Human Papillomavirus Infections – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 17
Late Stage Products, H2 2012 18
Mid Clinical Stage Products, H2 2012 19
Early Clinical Stage Products, H2 2012 20
Discovery and Pre-Clinical Stage Products, H2 2012 21
Assessment by Monotherapy Products, H2 2012 52
Assessment by Route of Administration, H2 2012 53
Assessment by Stage and Route of Administration, H2 2012 54
Assessment by Molecule Type, H2 2012 55
Assessment by Stage and Molecule Type, H2 2012 56

Customers who bought this item also bought

• Influenza A Infections - Pipeline Review, H2 2012
• Other Viral Infections - Pipeline Review, H2 2012
• Streptococcal Infections - Pipeline Review, H2 2012
• Bordetella Pertussis Infections - Pipeline Review, H2 2012
• Urinary Tract Infections - Pipeline Review, H2 2012
• Varicella Zoster (HHV-3) Infections - Pipeline Review, H2 2012
• Rotavirus Infections - Pipeline Review, H2 2012
• Clostridium Botulinum Infections - Pipeline Review, H2 2012
• Mycobacterium Infections - Pipeline Review, H2 2012
• Human Papillomavirus Infections - Pipeline Review, H1 2013